PDFLARGE FONT PDF

MEDITAB IRINOTECAN

Irinotecan hydrochloride


Consumer Medicine Information

What is in this leaflet

This leaflet answers some common questions about MEDITAB IRINOTECAN.

It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of treating you with MEDITAB IRINOTECAN against the expected benefits it will have for you.

Ask your doctor if you have any concerns about being treated with this medicine.

Keep this leaflet. You may need to read it again.

What MEDITAB IRINOTECAN is used for

MEDITAB IRINOTECAN is used to treat bowel cancer which has spread to other parts of the body. Cancer which has spread cannot be treated by surgery alone and one of the options in this situation is treatment with an anticancer medicine, known as chemotherapy.

MEDITAB IRINOTECAN may be used once spread of cancer beyond the bowel is first diagnosed. At this time MEDITAB IRINOTECAN will be given in combination with other anticancer medicines. Alternatively, MEDITAB IRINOTECAN is used alone when the cancer has not responded or has returned after initial treatment.

Ask your doctor if you have any questions about why MEDITAB IRINOTECAN has been prescribed for you.

Your doctor may have prescribed it for another purpose.

Use in children

It is not known if MEDITAB IRINOTECAN is safe and effective in the treatment of children.

Before being treated with MEDITAB IRINOTECAN

When MEDITAB IRINOTECAN must not be given

MEDITAB IRINOTECAN must not be given if you:

  • are allergic to irinotecan hydrochloride or any of the ingredients listed at the end of this leaflet
  • are or may become pregnant
  • are breastfeeding or intend to breastfeed

Before treatment with MEDITAB IRINOTECAN

You should only be treated with MEDITAB IRINOTECAN by a doctor who is experienced in treating patients with cancer. Treatment will normally take place in a hospital because of the need for hospital facilities and skilled personnel.

You will probably feel nauseous and have diarrhoea, vomiting, stomach cramping and possibly infections during or after treatment with MEDITAB IRINOTECAN.

It is likely that your doctor will give you one or more medicines before administering MEDITAB IRINOTECAN, which will help stop you vomiting or feeling sick after the treatment.

You will probably also have a blood test before each treatment.

You should tell your doctor if:

  • you are 65 years of age or older
  • you have or have had liver disease, kidney disease or heart disease
  • you have previously been treated with radiation therapy
  • you have diabetes or asthma
  • you have constipation or difficulty urinating
  • you have hereditary fructose intolerance
  • you have Criglar-Naijar syndrome or Gilbert’s syndrome
  • you are going to be vaccinated (have an injection to prevent a certain disease)

If you have not told your doctor about any of the above, tell your doctor before you are given MEDITAB IRINOTECAN.

Taking other medicines

Tell your doctor if you are taking any other medicines, including medicines that you buy without a prescription from a pharmacy, supermarket or health food shop.

Some medicines and MEDITAB IRINOTECAN may interfere with each other. In particular, tell your doctor if you are taking:

  • laxatives (e.g. for constipation)
  • diuretics (medicines which make you pass urine more frequently e.g. for heart disease)
  • any medicine for nausea or diarrhoea
  • dexamethasone (may be used to treat skin diseases, asthma or other allergic disorders)
  • anticonvulsants used to treat seizures
  • St Johns Wort, a herbal medicine used to treat depression
  • ketoconazole used to treat fungal infections.

Ask your doctor or other health care professional if you are not sure about this list of medicines. You may need to take different amounts of your medicines or you may need to use different medicines. Your doctor will advise you.

How MEDITAB IRINOTECAN is given

MEDITAB IRINOTECAN will be given to you by your doctor. It is diluted and given by slow infusion into a vein over a period of 90 minutes.

It is recommended that MEDITAB IRINOTECAN be given in different treatment courses depending on whether MEDITAB IRINOTECAN is given alone or in combination with other anticancer medicines.

When MEDITAB IRINOTECAN is given in combination, treatment courses are of 6 weeks duration given either weekly or fortnightly. Rest periods of 1 or 2 weeks are incorporated into the 6 week courses.

When MEDITAB IRINOTECAN is given alone, treatment courses include MEDITAB IRINOTECAN being given weekly for 4 weeks followed by a 2 week rest period and MEDITAB IRINOTECAN being given once every 3 weeks.

Depending on your response, treatment courses may be repeated more than once.

It is recommended that treatment with MEDITAB IRINOTECAN should be interrupted if you get severediarrhoea or other intolerable side effects.

Dose

The recommended dose for MEDITAB IRINOTECAN varies between 125 mg/m squared and 350 mg/m squared (based on body surface area), depending on the dosing schedule.

Your doctor will decide the dose of MEDITAB IRINOTECAN to be given.

Ask your doctor if you want more information about the dose of MEDITAB IRINOTECAN and the other medicines you will be receiving and how they are given.

After your first treatment course, the dose of MEDITAB IRINOTECAN may be increased by your doctor if you have not had too many side effects.

Your doctor will lower the dose or stop treatment if you have serious side effects, particularly diarrhoea or changes appearing in your blood tests.

In case of overdose

Overdose is unlikely as treatment will be given in hospital under the supervision of a doctor. The possible effects of overdose are the same as those listed below under Side effects.

Tell your doctor immediately if you do not feel well while being given MEDITAB IRINOTECAN.

While being treated with MEDITAB IRINOTECAN

Things you must do

Keep all appointments with your doctor and always discuss with your doctor any problems during or after treatment with MEDITAB IRINOTECAN.

Tell your doctor as soon as possible if diarrhoea occurs. Diarrhoea is a common side effect of MEDITAB IRINOTECAN. If untreated, severe diarrhoea can be life-threatening.

Your doctor will prescribe loperamide (an antidiarrhoeal) for you to take in case you get diarrhoea after treatment. You should start taking loperamide, when you first have poorly formed or loose stools or bowel movements more frequent than you would normally expect. You must tell your doctor if you cannot get diarrhoea under control within 24 hours after taking loperamide.

You should not take loperamide for more than 48 hours.

Also tell your doctor if you develop a fever in addition to the diarrhoea. In these cases, your doctor may give you antibiotics. If the diarrhoea or fever persists you may become dehydrated and need to go to hospital for treatment.

You may need to take antibiotics if there are changes in your blood tests indicating a lack of white blood cells. Symptoms of this may include frequent infections such as fever, severe chills, sore throat or mouth ulcers. If this persists, you may need to go to hospital for treatment.

If you have severe stomach cramps you may need to be treated with antibiotics.

You must use a reliable method of contraception (birth control) while being treated with MEDITAB IRINOTECAN. If pregnancy occurs, consult your doctor.

Things you must not do

Because of the risk of diarrhoea, do not take laxatives during treatment courses with MEDITAB IRINOTECAN. Talk to your doctor if you need more information about this.

Do not start taking any other medicines, prescription or not, without first telling your doctor or pharmacist.

Side effects

MEDITAB IRINOTECAN, like all other medicines, may cause unwanted side effects. Side effects are very common with anti-cancer medicines such as MEDITAB IRINOTECAN and they may be severe. Deaths have occurred which, in some cases, may have been related to treatment.

Tell your doctor immediately if you get any of the following side effects:

  • diarrhoea
  • start to vomit
  • develop a fever or any type of infection
  • fainting, light-headedness or dizziness
  • bloody or black stools
  • cannot eat or drink due to nausea or vomiting.

The above side effects may be serious. You may need urgent medical attention.

Very common side effects (occurring in over 50% of patients) are:

  • diarrhoea or stomach cramps; may occur early (during or shortly after a treatment) or late (usually more than 24 hours after treatment)
  • nausea, vomiting, loss of appetite
  • anaemia which may make you weak and light-headed or may cause you to faint
  • increased risk of infections including severe infections
  • weakness
  • hair loss.

Common side effects (occurring in 10-50% of patients) are:

  • constipation, flatulence (passing wind), sore mouth, heartburn
  • fever (increased body temperature), chills, headache, back pain or other types of pain, infection, fluid retention which results in swelling
  • weight loss, dehydration
  • runny nose or eyes, increased saliva, sweating or flushing
  • skin rash
  • coughing, difficulty breathing
  • difficulty sleeping or dizziness.

Less common side effects (occurring in less than 10% of patients) are:

  • increased risk of bleeding
  • severe fever associated with a reduction in white blood cell numbers
  • bleeding from the bowel
  • jaundice (yellowing of skin and eyes)
  • severe breathing difficulties
  • generally feeling unwell
  • abnormal manner of walking
  • fungal infections (e.g. thrush)
  • kidney problems
  • problems speaking.

In addition to the above side effects the following have also been reported:

  • allergic reactions; some of the symptoms of an allergic reaction may include: rash, itching or hives on the skin. In more severe cases symptoms may also include shortness of breath, wheezing or difficulty breathing, swelling of the face, lips, tongue or other parts of the body
  • pins and needles
  • abdominal bloating and/or pain
  • chest pains
  • hiccups.

Other side effects not listed above may happen in some people. Some of these side effects can only be found when your doctor does tests to check your progress.

Rare side effects of MEDITAB IRINOTECAN have also been reported. These include effects on the heart and blood vessels such as:

  • slowed heart beat
  • fainting
  • blackouts
  • blood clots
  • swelling and redness along a vein, which is extremely tender when touched
  • chest pains
  • heart attack
  • stroke.

Your doctor has information on monitoring for such side effects and their treatment. A very small number of patients have died suddenly while on MEDITAB IRINOTECAN.Tell your doctor as soon as possible if you experience any side effects, including any effects not listed above.

After treatment with MEDITAB IRINOTECAN

Storage

MEDITAB IRINOTECAN will normally be stored in a hospital. It should be stored below 25 degrees C and should be protected from light (kept in the packaging before use). MEDITAB IRINOTECAN must never be frozen.

Product description

What it looks like

MEDITAB IRINOTECAN is a sterile, clear, light yellow, solution in a vial. It is available in 2 sizes: 40 mg/2 mL and 100 mg/5 mL.

Each vial is for single use only and is contained in an outer carton.

Ingredients

The active ingredient in MEDITAB IRINOTECAN is irinotecan hydrochloride. There is 20 mg of irinotecan hydrochloride in each 1 mL of MEDITAB IRINOTECAN. MEDITAB IRINOTECAN also contains:
sorbitol,
lactic acid
Water for Injections.

It might also contain sodium hydroxide.

Supplier

MEDITAB IRINOTECAN is supplied in Australia by:

Cipla Australia Pty Ltd
Level 1, 132-136 Albert Road,
SOUTH MELBOURNE VIC 3205

Australian Registration Numbers

40 mg/2 mL: AUST R 167203

100 mg/5 mL: AUST R 167202

Date of preparation: January 2016

Published by MIMS November 2017

Consumers should be aware that the information provided by the Consumer Medicines Information (CMI) search (CMI Search) is for information purposes only and consumers should continue to obtain professional advice from a qualified healthcare professional regarding any condition for which they have searched for CMI. CMIs are provided by MIMS Australia. CMI is supplied by the relevant pharmaceutical company for each consumer medical product. All copyright and responsibility for CMI is that of the relevant pharmaceutical company. MIMS Australia uses its best endeavours to ensure that at the time of publishing, as indicated on the publishing date for each resource (e.g. Published by MIMS/myDr January 2007), the CMI provided was complete to the best of MIMS Australia's knowledge. The CMI and the CMI Search are not intended to be used by consumers to diagnose, treat, cure or prevent any disease or for any therapeutic purpose. Dr Me Pty Limited, its servants and agents shall not be responsible for the continued currency of the CMI, or for any errors, omissions or inaccuracies in the CMI and/or the CMI Search whether arising from negligence or otherwise or from any other consequence arising there from.